Federated Hermes Inc. Has $129.71 Million Stock Position in Natera, Inc. $NTRA

Federated Hermes Inc. lifted its position in Natera, Inc. (NASDAQ:NTRA) by 14.9% in the second quarter, Holdings Channel.com reports. The institutional investor owned 767,813 shares of the medical research company’s stock after buying an additional 99,789 shares during the period. Federated Hermes Inc.’s holdings in Natera were worth $129,714,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in NTRA. Vanguard Group Inc. grew its stake in Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after purchasing an additional 3,263,822 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the period. Geode Capital Management LLC increased its stake in Natera by 7.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after purchasing an additional 166,768 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Natera by 13.7% during the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock worth $287,908,000 after buying an additional 245,719 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, Director Roy D. Baynes sold 7,668 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $223.08, for a total transaction of $1,710,577.44. Following the transaction, the director directly owned 18,359 shares in the company, valued at approximately $4,095,525.72. The trade was a 29.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 160,703 shares of the company’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the sale, the chief executive officer directly owned 144,816 shares in the company, valued at $28,957,407.36. This trade represents a 52.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 307,687 shares of company stock worth $63,466,360 over the last 90 days. Company insiders own 5.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group upped their price target on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Piper Sandler upped their target price on shares of Natera from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 target price for the company in a report on Monday, October 27th. Evercore ISI boosted their price target on Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Finally, BTIG Research upped their price objective on Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Fifteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $223.53.

Natera Trading Up 1.0%

Shares of NTRA stock opened at $244.55 on Friday. The firm’s fifty day moving average price is $199.55 and its two-hundred day moving average price is $173.81. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $245.59. The firm has a market capitalization of $33.75 billion, a P/E ratio of -106.79 and a beta of 1.63.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue was up 34.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.26) EPS. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.